Tenaya Therapeutics, Inc. TNYA
Set alert
0.37 USD -0.03 -7.78%
At close · Oct 30
0.37 +0.01 +1.36%
After hours · Oct 30, 7:55 PM ET
0.3656 Day range 0.40
0.3674 52-week range 1.54
- YTD
- -48.40%
- 1 year
- -70.84%
- Open
- 0.398
- Prev close
- 0.3984
- Mkt cap
- 83.74M
- Vol
- 2.66M
- Avg vol
- 2.76M
- EPS
- -0.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3656
- High
- 0.40
- Forward P/E
- -1.28
- Beta
- 2.35
- Short ratio
- 2.31
- Inst. own
- 73.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.40
- 200-d avg
- 3.26
- 1y target
- 18.50
MAX chart
Events in this range
- Mar 18, 2024Earnings: -0.4; estimate -0.45; surprise 11.11%
- May 14, 2024Earnings: —; estimate -0.43; surprise —%
- May 14, 2024Earnings: -0.4; estimate -0.43; surprise 6.98%
- Aug 8, 2024Earnings: —; estimate -0.4; surprise —%
- Aug 8, 2024Earnings: -0.34; estimate -0.4; surprise 15%
- Oct 18, 2024Rating: Canaccord Genuity · Buy → Buy
- Nov 6, 2024Earnings: -0.3; estimate -0.37; surprise 18.92%
- Nov 7, 2024Rating: Chardan Capital · Buy → Buy
- Nov 25, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 26, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 18, 2024Rating: Chardan Capital · Buy → Buy
Signals (74)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 15, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| RSI: Overbought | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Jan 15, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| RSI: Oversold | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 19, 2023 | 3 years ago |
| RSI: Overbought | May 29, 2023 | 3 years ago |
| RSI: Overbought | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 27, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Feb 13, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| RSI: Oversold | Oct 31, 2022 | 4 years ago |
| RSI: Oversold | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 4, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 25, 2022 | 4 years ago |
| SMA: Bearish | Apr 11, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
| SMA: Bearish | Nov 15, 2021 | 4 years ago |
| SMA: Bullish | Oct 25, 2021 | 5 years ago |
| SMA: Bearish | Oct 11, 2021 | 5 years ago |
Key statistics
- Market cap
- 125.96M
- Enterprise value
- 67.37M
- Trailing P/E
- 0.00
- Forward P/E
- -1.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.12
- EPS (TTM)
- -1.44
- Beta
- 2.35
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -56.52M
- Total cash
- 79.47M
- Total debt
- 14.54M
- Return on equity
- -84.49%
- Shares outstanding
- 79.22M
- Short % of float
- 25.39%
- 50-day average
- 2.40
- 200-day average
- 3.26
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.50 +4935.4% upside
Now 0.3674
- Target (low)
- 6.00
- Target (mean)
- 18.50
- Target (high)
- 40.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.315.
Financials — quick view
TNYA Revenue — quarterly 1.11M
TNYA Net income — quarterly -43.39M
TNYA EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.37 | -0.30 | +0.07 | +18.92% |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.40 | -0.34 | +0.06 | +15.00% |
| May 14, 2024 | Mar 1, 2024 | -0.43 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.43 | -0.40 | +0.03 | +6.98% |
| Mar 18, 2024 | Dec 1, 2023 | -0.45 | -0.40 | +0.05 | +11.11% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Oct 18, 2024 | Canaccord Genuity | main | Buy | Buy |
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenayatherapeutics.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
- Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13
- Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201
- Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
- Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
- Earnings Scheduled For May 6, 2026
- Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate
- Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation
Your note
Sign in to keep a note on TNYA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI FARAZ | Chief Executive Officer | Sale | Aug 15, 2024 | 188,331 |
| COLUMN GROUP III GP, L.P | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| GOEDDEL DAVID V | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 11, 2024 | 0 |
| HOEY TIMOTHY | Officer | Sale | Mar 4, 2024 | 245,346 |
| PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2024 | 95,755 |
| SAITO CHIHIRO | Officer | Sale | Nov 17, 2024 | 60,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Column Group LLC | 11.87% | 9,400,290 | 14.95M | Sep 29, 2024 |
| RA Capital Management, L.P. | 8.81% | 6,982,587 | 11.10M | Sep 29, 2024 |
| Casdin Capital, LLC | 8.50% | 6,732,971 | 10.71M | Sep 29, 2024 |
| Blackrock Inc. | 5.18% | 4,106,305 | 6.53M | Sep 29, 2024 |
| Vanguard Group Inc | 4.06% | 3,213,167 | 5.11M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.82% | 3,028,435 | 4.82M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 2.65% | 2,099,086 | 3.34M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.61% | 2,064,246 | 3.28M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.20% | 1,746,113 | 2.78M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.80% | 1,428,719 | 2.27M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.87% | 691,525 | 1.10M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.72% | 567,023 | 901.57K | Aug 30, 2024 |